Yuhong Xu

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 13

Top Venues

Pharmaceutical research

Methods in molecular biology (Clifton, N.J.)

ACS applied materials & interfaces

Cancer immunology, immunotherapy : CII

Hangzhou Highfield Biopharmaceuticals Inc.

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Hangzhou Highfield Biopharmaceuticals Inc. Jan 01 2020

China

Managing Director

Dali University Jan 01 2020

China

Professor :: School of Pharmacy and Chemistry

Publications

ShanShan Jin, Huimin Li, Yuhong Xu
Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes). Methods in molecular biology (Clifton, N.J.) 2622 (2023)
ShanShan Jin, Huimin Li, Yuhong Xu
Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes). Methods in molecular biology (Clifton, N.J.) 2622 (2023)
Fang Xie, Luchen Zhang, Sanyuan Shi, Anjie Zheng, Jiaxing Di, Shanshan Jin, Xuguang Miao, Fenglan Wu, Xiaolong Chen, Yanhong Zhang, Xiaohui Wei, Yuhong Xu
Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy. mAbs 14 (1) (2022)
Jiaxing Di, Zhili Du, Kangzeng Wu, Shanshan Jin, Xun Wang, Tonglei Li, Yuhong Xu
Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size. Pharmaceutical research 39 (1) (2022)
Huimin Li, Jiaxing Di, Baowei Peng, Yuhong Xu, Ning Zhang
Surface Ligand Valency and Immunoliposome Binding: when More Is Not Always Better. Pharmaceutical research 38 (9) (2021)
Ran Ye, Yuan Zheng, Yang Chen, Xiaohui Wei, Sanyuan Shi, Yuetan Chen, Wanxin Zhu, Anqi Wang, Liuxin Yang, Yuhong Xu, Jinliang Peng
Stable Loading and Delivery of Melittin with Lipid-Coated Polymeric Nanoparticles for Effective Tumor Therapy with Negligible Systemic Toxicity. ACS applied materials & interfaces 13 (47) (2021)
Junye Liu, Anjie Zheng, Baowei Peng, Yuhong Xu, Ning Zhang
Size-Dependent Absorption through Stratum Corneum by Drug-Loaded Liposomes. Pharmaceutical research 38 (8) (2021)
Fenglan Wu, Yangsheng Qiu, Yuhong Xu
A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities. Cancer immunology, immunotherapy : CII 69 (12) (2020)
Qianru Yu, Maxin Zhang, Yuetan Chen, Xiaolong Chen, Sanyuan Shi, Kang Sun, Ran Ye, Yuan Zheng, Yang Chen, Yuhong Xu, Jinliang Peng
Self-Assembled Nanoparticles Prepared from Low-Molecular-Weight PEI and Low-Generation PAMAM for EGFRvIII-Chimeric Antigen Receptor Gene Loading and T-Cell Transient Modification. International journal of nanomedicine 15 (2020)
Wangxi Hai, Xiao Bao, Kang Sun, Biao Li, Jinliang Peng, Yuhong Xu
The Labeling, Visualization, and Quantification of Hyaluronan Distribution in Tumor-Bearing Mouse Using PET and MR Imaging. Pharmaceutical research 37 (12) (2020)
Caixing Wu, Xiaofei Xiang, Yang Yue, Lin Li, Yesen Li, Chong Zhang, Yuhong Xu
CpG-PEG Conjugates and their Immune Modulating Effects after Systemic Administration. Pharmaceutical research 35 (4) (2018)
Chong Li, Jing Cao, Ning Zhang, Meiqing Tu, Fengwei Xu, Shuang Wei, Xiaojing Chen, Yuhong Xu
Identification of RSPO2 Fusion Mutations and Target Therapy Using a Porcupine Inhibitor. Scientific reports 8 (1) (2018)
Yonghui Li, Yan Han, Xiaoya Wang, Jinliang Peng, Yuhong Xu, Jiang Chang
Multifunctional Hydrogels Prepared by Dual Ion Cross-Linking for Chronic Wound Healing. ACS applied materials & interfaces 9 (19) (2017)

Yuhong Xu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yuhong Xu